RHJA
ADMS

Rice Hall James & Associates’s Adamas Pharmaceuticals ADMS Stock Holding History

Rice Hall James & Associates’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-82,413
Closed -$586K – 302
2019
Q1 		$586K Buy
82,413
+59,485
+259% +$535K 0.02% 266
2018
Q4 		$196K Buy
22,928
+5,810
+34% +$75.6K 0.01% 291
2018
Q3 		$343K Buy
+17,118
New +$402K 0.01% 283

Other funds holding ADMS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Rice Hall James & Associates's ADMS Position: Q2 2019 in Review

Rice Hall James & Associates sold out of Adamas Pharmaceuticals (ADMS) in Q2 2019, closing a stake of 82,413 shares — an estimated $586K sold.

Rice Hall James & Associates first reported a position in ADMS in Q3 2018 and held it in 3 quarters. The position peaked at $586K in Q1 2019. 78 funds tracked by Wall St. Rank hold ADMS as of Q2 2019.

  • Rice Hall James & Associates reported no remaining Adamas Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Rice Hall James & Associates sold 82,413 Adamas Pharmaceuticals shares in Q2 2019, an estimated $586K.
  • Rice Hall James & Associates first reported a position in Adamas Pharmaceuticals in Q3 2018 and held it in 3 quarters.
  • Rice Hall James & Associates's Adamas Pharmaceuticals position peaked at $586K in Q1 2019.
  • 78 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q2 2019.

Based on Rice Hall James & Associates's 13F filing for Q2 2019, filed 1 Aug 2019.